Xilio Therapeutics (XLO) Non-Current Debt (2020 - 2023)

Xilio Therapeutics has disclosed Non-Current Debt across 4 years of filings, most recently posting $1.5 million for Q1 2023.

• In Q1 2023, Non-Current Debt fell 80.68% year-over-year to $1.5 million; the TTM figure through Mar 2023 stood at $1.5 million (down 80.68% YoY), while the FY2022 annual figure was $3.2 million, down 67.13% from the prior year.
• Non-Current Debt came in at $1.5 million for Q1 2023 at Xilio Therapeutics, down from $3.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $9.6 million in Q4 2021 to a low of $1.5 million in Q1 2023.
• Average Non-Current Debt over 4 years is $6.3 million, with a median of $6.9 million recorded in 2020.
• Year-over-year, Non-Current Debt grew 29.9% in 2021 and sank 80.68% in 2023.
• Over 4 years, Non-Current Debt stood at $7.4 million in 2020, then climbed by 29.9% to $9.6 million in 2021, then slumped by 67.13% to $3.2 million in 2022, then slumped by 51.09% to $1.5 million in 2023.
• Per Business Quant data, the three most recent Non-Current Debt figures were $1.5 million in Q1 2023, $3.2 million in Q4 2022, and $4.8 million in Q3 2022.